Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

Lung metastases are the second most common malignant neoplasms of the lung. It is estimated that 20–54% of cancer patients have lung metastases at some point during their disease course, and at least 50% of cancer-related deaths occur at this stage. Lung metastases are widely accepted to be oligomet...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez, Enrique, Sánchez, Irving, Díaz, Omar, Valles, Adrián, Balderrama, Ricardo, Fuentes, Jesús, Lara, Brenda, Olimón, Cipatli, Ruiz, Víctor, Rodríguez, José, Bayardo, Luis H., Chan, Matthew, Villafuerte, Conrad J., Padayachee, Jerusha, Sun, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293144/
https://www.ncbi.nlm.nih.gov/pubmed/34287274
http://dx.doi.org/10.3390/curroncol28040233
Descripción
Sumario:Lung metastases are the second most common malignant neoplasms of the lung. It is estimated that 20–54% of cancer patients have lung metastases at some point during their disease course, and at least 50% of cancer-related deaths occur at this stage. Lung metastases are widely accepted to be oligometastatic when five lesions or less occur separately in up to three organs. Stereotactic body radiation therapy (SBRT) is a noninvasive, safe, and effective treatment for metastatic lung disease in carefully selected patients. There is no current consensus on the ideal dose and fractionation for SBRT in lung metastases, and it is the subject of study in ongoing clinical trials, which examines different locations in the lung (central and peripheral). This review discusses current indications, fractionations, challenges, and technical requirements for lung SBRT.

Ejemplares similares